ArticleNoro psikiyatri arsivi2026
CHI3L1 and CXCL13 Levels of Serum and CSF in Treatment-Naïve Multiple Sclerosis: Associations with Disease Activity.
Article in Noro psikiyatri arsivi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cytokines, intracellular polypeptides, and chemokines, which belong to a small protein superfamily, are crucial in regulating inflammation and cell migration. Profiling these molecules can offer significant insights into the inflammatory process and aid in predicting disease outcomes. This study seeks to quantify cytokine and chemokine levels in serum and cerebrospinal fluid (CSF) samples from treatment-naïve patients, both with and without poor prognostic indicators, to identify biomarkers indicative of disease activity. Methods: A prospective, observational, cross-sectional study was carried out involving patients diagnosed with Multiple sclerosis (MS) or non-inflammatory neurological disorders at Marmara University Faculty of Medicine. Multiple sclerosis patients were further classified into two groups based on previously established clinical and radiological criteria: those with poor prognostic outcomes and those without. Levels of IL-8, IL-12/IL-23p40, IL-21, CHI3L1, and CXCL13 were measured in both CSF and serum samples using the ELISA method. Statistical analyses were conducted using Stata version 15.1. Results: A total of 56 patients participated in the study. CHI3L1 (p=0.003) and CXCL13 (p<0.001) levels in CSF were significantly elevated in MS patients compared to the control group. Among the MS cohort, serum CXCL13 levels positively correlated with the EDSS score (p=0.04, r=0.39) and the number of spinal cord lesions (p=0.009, r=0.48). Additionally, a significant negative correlation was observed between CSF CXCL13 levels and patient age in the MS group (p=0.03, r=-0.42). Conclusion: Increased CSF levels of CHI3L1 and CXCL13 may serve as potential diagnostic markers for Relapsing-Remitting MS (RRMS) patients. Given the ease of collecting serum samples, further research is necessary to explore the relationship between serum CXCL13 levels, EDSS scores, and spinal cord lesions in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.